Clinical Trials Logo
  1. Home
  2. Chronic Myeloid Leukemia (CML)
  3. NCT04126707

The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans

Chronic Myeloid Leukemia (CML) Clinical Trial

Official title:
A Single-center, Open-label, Single-dose Phase I Study to Investigate the Absorption, Metabolism and Excretion of [14C] HQP1351 After a Single Oral 30mg (100µCi) Dose in Healthy Chinese Male Subjects

Clinical Trial Summary

The objective of this study is to determine the mass balance and routes of excretion of total radioactivity after a single oral 30mg (100µCi) dose of [14C] HQP1351 given as a suspension. For further clinical development, human mass balance data are required to elucidate the absorption, metabolism, and excretion of HQP1351.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04126707
Study type Interventional
Source Ascentage Pharma Group Inc.
Contact
Status Completed
Phase Phase 1
Start date November 19, 2019
Completion date January 13, 2020
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01066468 - Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. Phase 1
Completed NCT00428909 - Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Phase 1
Active, not recruiting NCT02061800 - CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant Phase 1/Phase 2
Completed NCT00488592 - Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers Phase 2
Terminated NCT03615105 - Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors Phase 2
Recruiting NCT02790515 - Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Phase 2
Active, not recruiting NCT03849651 - TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies Phase 2
Withdrawn NCT01605981 - Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. Phase 4
Completed NCT02363868 - Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population N/A
Completed NCT00433745 - Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy Phase 2
Not yet recruiting NCT04709731 - Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia Phase 2
Recruiting NCT03481868 - EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors N/A
Recruiting NCT02889003 - Second STOP After Pioglitazone Priming in CML Patients Phase 2
Completed NCT02733445 - Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib N/A
Active, not recruiting NCT03746054 - Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality Phase 3
Completed NCT01667133 - A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Phase 1/Phase 2
Completed NCT00720785 - Natural Killer Cells and Bortezomib to Treat Cancer Phase 1
Recruiting NCT05963061 - Chronic Myeloid Leukemia (CML) Real-Life Database
Approved for marketing NCT01592136 - Expanded Access Program of Ponatinib N/A